Peptide-induced HLA-E expression in human PBMCs is dependent on peptide sequence and the HLA-E genotype

Tissue Antigens

Volumn 85, Issue 4, 2015, Pages 242-251

  Lauterbach, N ^a   Wieten, L ^a   Popeijus, H E ^b   Vanderlocht, J ^a   van Zon, P M H ^a   Voorter, C E M ^a   Tilanus, M G J ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Cytomegalovirus (CMV); Human leukocyte antigen (HLA) E expression; Human leukocyte antigen (HLA) E polymorphism; Peptide; Transplantation

Indexed keywords

COMPLEMENTARY DNA; HLA E ANTIGEN; PEPTIDE; RNA; CHAPERONIN 60; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA C ANTIGEN; HLA-E ANTIGEN; HSPD1 PROTEIN, HUMAN; MESSENGER RNA; MITOCHONDRIAL PROTEIN;

AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; ARTICLE; CELL LYSATE; CONTROLLED STUDY; CYTOMEGALOVIRUS; FLOW CYTOMETRY; GENE EXPRESSION; GENOTYPE; HLA SYSTEM; HOST RESISTANCE; HUMAN; HUMAN CELL; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; STEM CELL TRANSPLANTATION; T LYMPHOCYTE SUBPOPULATION; VIRUS INFECTION; WESTERN BLOTTING; CHEMISTRY; CYTOLOGY; CYTOTOXICITY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HOMOZYGOTE; IMMUNOLOGY; MOLECULAR GENETICS; MONONUCLEAR CELL; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

CYTOMEGALOVIRUS;

AMINO ACID SEQUENCE; CHAPERONIN 60; CYTOMEGALOVIRUS; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION REGULATION; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-B ANTIGENS; HLA-C ANTIGENS; HOMOZYGOTE; HUMANS; LEUKOCYTES, MONONUCLEAR; MITOCHONDRIAL PROTEINS; MOLECULAR SEQUENCE DATA; PEPTIDES; PRIMARY CELL CULTURE; RNA, MESSENGER; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84925303296     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/tan.12525     Document Type: Article

References (44)

1. Pietra G, Romagnani C, Mazzarino P et al. HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes. Proc Natl Acad Sci U S A 2003: 100: 10896-901.
2. Romagnani C, Pietra G, Falco M, Mazzarino P, Moretta L, Mingari MC. HLA-E-restricted recognition of human cytomegalovirus by a subset of cytolytic T lymphocytes. Hum Immunol 2004: 65: 437-45.
3. Mazzarino P, Pietra G, Vacca P et al. Identification of effector-memory CMV-specific T lymphocytes that kill CMV-infected target cells in an HLA-E-restricted fashion. Eur J Immunol 2005: 35: 3240-7.
4. Kaiser BK, Barahmand-Pour F, Paulsene W, Medley S, Geraghty DE, Strong RK. Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. J Immunol 2005: 174: 2878-84.
5. Kaiser BK, Pizarro JC, Kerns J, Strong RK. Structural basis for NKG2A/CD94 recognition of HLA-E. Proc Natl Acad Sci U S A 2008: 105: 6696-701.
6. Lee N, Llano M, Carretero M et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A 1998: 95: 5199-204.
7. Braud VM, Allan DS, O'Callaghan CA et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998: 391: 795-9.
8. Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J Immunol 1998: 160: 4951-60.
9. Maier S, Grzeschik M, Weiss EH, Ulbrecht M. Implications of HLA-E allele expression and different HLA-E ligand diversity for the regulation of NK cells. Hum Immunol 2000: 61: 1059-65.
10. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med 1998: 187: 813-8.
11. Braud V, Jones EY, McMichael A. The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur J Immunol 1997: 27: 1164-9.
12. Ulbrecht M, Martinozzi S, Grzeschik M et al. Cutting edge: the human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis. J Immunol 2000: 164: 5019-22.
13. Heinzel AS, Grotzke JE, Lines RA et al. HLA-E-dependent presentation of Mtb-derived antigen to human CD8+ T cells. J Exp Med 2002: 196: 1473-81.
14. Michaelsson J, Teixeira de Matos C, Achour A, Lanier LL, Karre K, Soderstrom K. A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. J Exp Med 2002: 196: 1403-14.
15. van Hall T, Oliveira CC, Joosten SA, Ottenhoff TH. The other Janus face of Qa-1 and HLA-E: diverse peptide repertoires in times of stress. Microbes Infect 2010: 12: 910-8.
16. Marin R, Ruiz-Cabello F, Pedrinaci S et al. Analysis of HLA-E expression in human tumors. Immunogenetics 2003: 54: 767-75.
17. Robinson J, Halliwell JA, McWilliam H, Lopez R, Parham P, Marsh SG. The IMGT/HLA database. Nucleic Acids Res 2013: 41: D1222-7.
18. Geraghty DE, Stockschleader M, Ishitani A, Hansen JA. Polymorphism at the HLA-E locus predates most HLA-A and -B polymorphism. Hum Immunol 1992: 33: 174-84.
19. Grimsley C, Ober C. Population genetic studies of HLA-E: evidence for selection. Hum Immunol 1997: 52: 33-40.
20. Tamouza R, Rocha V, Busson M et al. Association of HLA-E polymorphism with severe bacterial infection and early transplant-related mortality in matched unrelated bone marrow transplantation. Transplantation 2005: 80: 140-4.
21. Tamouza R, Busson M, Rocha V et al. Homozygous status for HLA-E*0103 confers protection from acute graft-versus-host disease and transplant-related mortality in HLA-matched sibling hematopoietic stem cell transplantation. Transplantation 2006: 82: 1436-40.
22. Ludajic K, Rosenmayr A, Fae I et al. Association of HLA-E polymorphism with the outcome of hematopoietic stem-cell transplantation with unrelated donors. Transplantation 2009: 88: 1227-8.
23. Danzer M, Polin H, Proll J et al. Clinical significance of HLA-E*0103 homozygosity on survival after allogeneic hematopoietic stem-cell transplantation. Transplantation 2009: 88: 528-32.
24. Hosseini E, Schwarer AP, Jalali A, Ghasemzadeh M. The impact of HLA-E polymorphisms on relapse following allogeneic hematopoietic stem cell transplantation. Leuk Res 2013: 37: 516-9.
25. Hosseini E, Schwarer AP, Ghasemzadeh M. The impact of HLA-E polymorphisms in graft-versus-host disease following HLA-E matched allogeneic hematopoietic stem cell transplantation. Iran J Allergy Asthma Immunol 2012: 11: 15-21.
26. Ulbrecht M, Couturier A, Martinozzi S et al. Cell surface expression of HLA-E: interaction with human beta2-microglobulin and allelic differences. Eur J Immunol 1999: 29: 537-47.
27. Strong RK, Holmes MA, Li P, Braun L, Lee N, Geraghty DE. HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities. J Biol Chem 2003: 278: 5082-90.
28. Voltz R, Jilg W, Wolf H. Modification of HLA expression as a possible factor in the pathogenesis of Burkitt's lymphoma. Haematol Blood Transfus 1989: 32: 289-92.
29. Paco L, Garcia-Lora AM, Casares C et al. Total loss of HLA class I expression on a melanoma cell line after growth in nude mice in absence of autologous antitumor immune response. Int J Cancer 2007: 121: 2023-30.
30. Chang CC, Murphy SP, Ferrone S. Differential in vivo and in vitro HLA-G expression in melanoma cells: potential mechanisms. Hum Immunol 2003: 64: 1057-63.
31. Llano M, Lee N, Navarro F et al. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol 1998: 28: 2854-63.
32. Miller JD, Weber DA, Ibegbu C, Pohl J, Altman JD, Jensen PE. Analysis of HLA-E peptide-binding specificity and contact residues in bound peptide required for recognition by CD94/NKG2. J Immunol 2003: 171: 1369-75.
33. Cheent KS, Jamil KM, Cassidy S et al. Synergistic inhibition of natural killer cells by the nonsignaling molecule CD94. Proc Natl Acad Sci U S A 2013: 110: 16981-6.
34. Lauterbach N, Voorter CE, Tilanus MG. Molecular typing of HLA-E. Methods Mol Biol 2012: 882: 143-58.
35. Sarkar S, Germeraad WT, Rouschop KM et al. Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells. PLoS One 2013: 8: e64835.
36. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001: 29: e45.
37. Sui H, Zhou S, Wang Y et al. COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer. Carcinogenesis 2011: 32: 667-75.
38. Paquay MM, Schellekens J, Tilanus MG. A high-throughput Taqman approach for the discrimination of HLA-E alleles. Tissue Antigens 2009: 74: 514-9.
39. Mahmutefendic H, Blagojevic G, Kucic N, Lucin P. Constitutive internalization of murine MHC class I molecules. J Cell Physiol 2007: 210: 445-55.
40. Veiga-Castelli LC, Felicio LP, Georg RC, Castelli EC, Donadi EA. A nonsynonymous mutation at HLA-E defines the new E*01:06 allele in Brazilian individuals. Tissue Antigens 2013: 82: 216-7.
41. Wieten L, Mahaweni NM, Voorter CE, Bos GM, Tilanus MG. Clinical and immunological significance of HLA-E in stem cell transplantation and cancer. Tissue Antigens 2014: 84: 523-35.
42. Enqvist M, Nilsonne G, Hammarfjord O et al. Selenite induces posttranscriptional blockade of HLA-E expression and sensitizes tumor cells to CD94/NKG2A-positive NK cells. J Immunol 2011: 187: 3546-54.
43. Skov S. Intracellular signal transduction mediated by ligation of MHC class I molecules. Tissue Antigens 1998: 51: 215-23.
44. Al-Daccak R, Mooney N, Charron D. MHC class II signaling in antigen-presenting cells. Curr Opin Immunol 2004: 16: 108-13.